Methods of reducing vascular permeability in tissue by inhibition of tissue plasminogen activator (tPA) and tPA inhibitors useful therein
View Patent ↗The present invention is a method of reducing vascular permeability in tissue of a subject comprising inhibiting the activity of serine proteinase tissue-type plasminogen activator (tPA). This tPA activity which increases permeability of the tissue in a subject results in edema in the tissue is separate from tPA's thrombolytic activity. The present invention more specifically relates to administering an amount of a tPA inhibitor sufficient to reduce the vascular permeability increasing activity of tPA in a subject. Useful tPA inhibitors for the present method are neuroserpin, mutant neuroserpin, wild-type PAI-1, mutant PAI-1, an antibody that binds to tPA, an antibody that binds to the low-density lipoprotein (LDL) receptor or a low-density lipoprotein (LDL) receptor family antagonist.
1. A method of reducing vascular permeability in tissue comprising the step of administering to a subject in need thereof a therapeutically effective amount of a tissue plasminogen activator (tPA) inhibitor of tPA interaction with a low density lipoprotein (LDL) receptor-related protein (LRP) sufficient to reduce the vascular permeability increasing activity of the tPA.
2. The method of claim 1 , wherein said activity of tPA which increases vascular permeability is independent of its interaction with plasminogen conversion to plasmin.
3. The method of claim 2 , wherein said increase in vascular permeability in the tissue results in edema in the tissue.
4. The method of claim 3 , wherein said edema in the tissue is a result of an injury, a condition, a disease or a disorder of said subject.
5. The method of claim 4 , wherein said injury, condition, disease or disorder is selected from the group consisting of a head trauma, pulmonary edema, peripheral vascular disease, ischemic stroke, cystitis, pancreatitis, brain tumor, spinal cord tumor, spinal cord trauma, polymyositis, dermatomyositis, pulmonary embolism, enterocolitis, hepatic congestion, cerebral venous thrombosis, intracerebral hemorrhage, post-surgical manipulation, nephritis and glomerulonephritis, brain injury and sepsis.
6. The method of claim 4 , wherein said edema is associated with an injury, trauma, disorder or disease to the brain in which increased vascular permeability results in the loss of the integrity of the blood brain barrier.
7. The method of claim 2 , wherein said tPA inhibitor is administered intravenuously, intrathecally or via nasal administration so that it reaches the tissue.
8. The method of claim 7 , wherein said tPA inhibitor is associated with lipids to facilitate delivery to the tissue.
9. The method of claim 2 , wherein said tPA inhibitor is administered simultaneously with tPA and in a therapeutically effective amount to inhibit the vascular permeability increasing activity of tPA.
10. The method of claim 2 , wherein said tPA inhibitor decreases the tPA-induced blood brain barrier permeability in said subject.
11. The method of claim 2 , wherein said tPA inhibitor inhibits the binding of tPA to a low-density lipoprotein (LDL) receptor family protein.
12. The method of claim 11 , wherein said LDL receptor family protein comprises a low-density lipoprotein receptor-related protein (LRP).
13. The method of claim 12 , wherein said tPA inhibitor is the receptor associate protein (RAP).
14. The method of claim 2 , wherein said tPA inhibitor inhibits the proteolytic activity of tPA.
15. The method of claim 14 , wherein said tPA inhibitor is a proteinase inhibitor.
16. The method of claim 14 , wherein said tPA inhibitor is neuroserpin, mutant neuroserpin, wild-type PAl-1, mutant PAl-I or an antibody that binds to tPA.
17. The method of claim 2 , wherein said tPA inhibitor is neuroserpin, mutant neuroserpin, wild-type PAl-1, mutant PAl-1, an antibody that binds to tPA, an antibody that binds to the low-density lipoprotein (LDL) receptor or a low-density lipoprotein (LDL) receptor family antagonist.
18. The method of claim 17 , wherein said LDL receptor family antagonist is the receptor associate protein (RAP).